196 related articles for article (PubMed ID: 17079360)
1. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans.
Gurley BJ; Swain A; Barone GW; Williams DK; Breen P; Yates CR; Stuart LB; Hubbard MA; Tong Y; Cheboyina S
Drug Metab Dispos; 2007 Feb; 35(2):240-5. PubMed ID: 17079360
[TBL] [Abstract][Full Text] [Related]
2. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo.
Gurley BJ; Swain A; Hubbard MA; Hartsfield F; Thaden J; Williams DK; Gentry WB; Tong Y
Clin Pharmacol Ther; 2008 Jan; 83(1):61-9. PubMed ID: 17495878
[TBL] [Abstract][Full Text] [Related]
3. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans.
Gurley BJ; Barone GW; Williams DK; Carrier J; Breen P; Yates CR; Song PF; Hubbard MA; Tong Y; Cheboyina S
Drug Metab Dispos; 2006 Jan; 34(1):69-74. PubMed ID: 16221754
[TBL] [Abstract][Full Text] [Related]
4. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics.
Gurley BJ; Swain A; Williams DK; Barone G; Battu SK
Mol Nutr Food Res; 2008 Jul; 52(7):772-9. PubMed ID: 18214850
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes.
Gurley BJ; Gardner SF; Hubbard MA; Williams DK; Gentry WB; Khan IA; Shah A
Clin Pharmacol Ther; 2005 May; 77(5):415-26. PubMed ID: 15900287
[TBL] [Abstract][Full Text] [Related]
6. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea.
Gurley BJ; Swain A; Hubbard MA; Williams DK; Barone G; Hartsfield F; Tong Y; Carrier DJ; Cheboyina S; Battu SK
Mol Nutr Food Res; 2008 Jul; 52(7):755-63. PubMed ID: 18214849
[TBL] [Abstract][Full Text] [Related]
7. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
Greiner B; Eichelbaum M; Fritz P; Kreichgauer HP; von Richter O; Zundler J; Kroemer HK
J Clin Invest; 1999 Jul; 104(2):147-53. PubMed ID: 10411543
[TBL] [Abstract][Full Text] [Related]
8. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.
Gurley B; Hubbard MA; Williams DK; Thaden J; Tong Y; Gentry WB; Breen P; Carrier DJ; Cheboyina S
J Clin Pharmacol; 2006 Feb; 46(2):201-13. PubMed ID: 16432272
[TBL] [Abstract][Full Text] [Related]
9. An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations.
Nguyen JT; Tian DD; Tanna RS; Arian CM; Calamia JC; Rettie AE; Thummel KE; Paine MF
J Pharmacol Exp Ther; 2023 Dec; 387(3):252-264. PubMed ID: 37541764
[TBL] [Abstract][Full Text] [Related]
10. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
Reitman ML; Chu X; Cai X; Yabut J; Venkatasubramanian R; Zajic S; Stone JA; Ding Y; Witter R; Gibson C; Roupe K; Evers R; Wagner JA; Stoch A
Clin Pharmacol Ther; 2011 Feb; 89(2):234-42. PubMed ID: 21191377
[TBL] [Abstract][Full Text] [Related]
11. Influence of goldenseal root on the pharmacokinetics of indinavir.
Sandhu RS; Prescilla RP; Simonelli TM; Edwards DJ
J Clin Pharmacol; 2003 Nov; 43(11):1283-8. PubMed ID: 14551183
[TBL] [Abstract][Full Text] [Related]
12. Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?
Baris N; Kalkan S; Güneri S; Bozdemir V; Guven H
Eur J Clin Pharmacol; 2006 Jul; 62(7):535-8. PubMed ID: 16767433
[TBL] [Abstract][Full Text] [Related]
13. Impact of ginkgo biloba on the pharmacokinetics of digoxin.
Mauro VF; Mauro LS; Kleshinski JF; Khuder SA; Wang Y; Erhardt PW
Am J Ther; 2003; 10(4):247-51. PubMed ID: 12845387
[TBL] [Abstract][Full Text] [Related]
14. The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers.
Tsutsumi K; Kotegawa T; Kuranari M; Otani Y; Morimoto T; Matsuki S; Nakano S
J Clin Pharmacol; 2002 Oct; 42(10):1159-64. PubMed ID: 12362931
[TBL] [Abstract][Full Text] [Related]
15. Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin.
Zussman BD; Kelly J; Murdoch RD; Clark DJ; Mbchb ; Schubert C; Collie H
Clin Ther; 2001 Jun; 23(6):921-31. PubMed ID: 11440291
[TBL] [Abstract][Full Text] [Related]
16. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.
Weber P; Lettieri JT; Kaiser L; Mazzu AL
Clin Ther; 1999 Sep; 21(9):1563-75. PubMed ID: 10509851
[TBL] [Abstract][Full Text] [Related]
17. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Neuhoff S; Yeo KR; Barter Z; Jamei M; Turner DB; Rostami-Hodjegan A
J Pharm Sci; 2013 Sep; 102(9):3161-73. PubMed ID: 23686764
[TBL] [Abstract][Full Text] [Related]
18. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects.
Vaz da Silva M; Costa R; Soares E; Maia J; Falcão A; Almeida L; Soares da Silva P
Fundam Clin Pharmacol; 2009 Aug; 23(4):509-14. PubMed ID: 19500154
[TBL] [Abstract][Full Text] [Related]
19. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
Liu F; Vessey L; Wenning L; Connolly S; Buckland M; Johnson-Levonas AO; Denker A; Wagner JA; Lai E
J Clin Pharmacol; 2010 Jul; 50(7):823-8. PubMed ID: 20197486
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
Denker AE; Morelli G; Vessey LK; Li S; Yuan J; Dunbar S; Lewis NM; Taggart W; Wagner JA
Adv Ther; 2009 Feb; 26(2):230-40. PubMed ID: 19219408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
